Can I read Tolebrutinib Delays Disability in MS Study on EtoBox?

Tolebrutinib Delays Disability in MS Study by busraisci61 is a document available to read on EtoBox.

What is Tolebrutinib Delays Disability in MS Study about?

Tolebrutinib has shown a 31% delay in confirmed disability progression in a phase 3 study for non-relapsing secondary progressive multiple sclerosis, with results presented at ECTRIMS 2024. The drug also demonstrated a nearly two-fold increase in confirmed disability improvement compared to placebo. Global regulatory submissions for tolebrutinib are expected to begin in the second half of 2024.

Author

busraisci61

Language

EN